By: Dividend Sensei
This blue-chip is one of the most successful pharma giants when it comes to sales and cash flow-boosting mergers and acquisitions. This company hasn’t cut it since at least 1985, and it’s working with a 13-year growth streak right now. It’s risk-adjusted expected returns are more than 7X that of the S&P 500. If it grows at the 6% to 12% CAGR that analysts expect there’s a 90% probability it will deliver market-beating returns over the next decade.